Back to News & Events

Funding Opportunity: Long Island Bioscience Hub REACH

The Center for Biotechnology, on behalf of Long Island Bioscience Hub (LIBH), is pleased to announce the opening of the 8th round of the LIBH Technology Development RFP.

Two specific funding programs have been designed to help faculty, physicians, surgeons, medical fellows, and post-docs develop their academic innovations toward commercial goals. The RFP is and forms for the funding programs can be found on the Center for Biotechnology website here.

Those interested in applying are strongly encouraged to discuss the proposal with:
Anton Xavier (anton.xavier@stonybrook.edu)
William Hanes (william.hanes@stonybrook.edu)
Heather Bielski Lawler (heather.bielski@stonybrook.edu)
Johnna St Clair (johnna.stclair@stonybrook.edu)

They are happy to introduce this Technology Development program and provide support to address unfamiliar questions in the application.

Deadline for submission is Sep 13th, 2019. All proposal should be submitted through the online portal HERE. Please note an approval from your Sponsored Programs Office is NOT required prior to the submission but will be required if the project is selected for NIH secondary review. Eligible applicants will be notified if their application is selected to move forward.

The Center for Biotechnology, in collaboration with Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research, formed the LIBH. A principal goal of the LIBH is to foster the development of therapeutics, diagnostics, devices and research tools emerging from within the four partner institutions that address diseases within the mission of NIH. The LIBH is supported by the National Institutes of Health REACH initiative (Research Evaluation and Commercialization Hub), our four partner institutions, The Research Foundation for SUNY, and Empire State Development.

 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4285
                    [post_author] => 4
                    [post_date] => 2023-09-11 12:13:16
                    [post_date_gmt] => 2023-09-11 16:13:16
                    [post_content] => 

Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”

The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.

Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include:
– Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital
– Doreen Swift, Senior Director, Embedded Software Engineering, IPS
– Michael R. Bielski, President, DevTech Partners
– Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University
– Paul Schwartz, Director, Advanced Propulsion Technologies

This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.

For more information visit: https://www.stonybrook.edu/commcms/ipp/Events/Manufacturing.php

[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23 [post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.” [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23 [to_ping] => [pinged] => [post_modified] => 2023-11-15 11:24:35 [post_modified_gmt] => 2023-11-15 16:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4285 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2190 [post_author] => 3 [post_date] => 2016-05-05 07:00:27 [post_date_gmt] => 2016-05-05 07:00:27 [post_content] => Accelerating the development of biomedical technologies The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), has announced the recipients of the second round of funded projects under the Hub’s technology development and commercialization initiative. Funding for ten projects totaling $600,000 was awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute at Northwell Health Systems. The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. There are two tiers of funding, each with the goal of accelerating technology development to reach a critical development inflection point. Feasibility awards ($50,000) are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept Awards ($100,000) provide targeted, milestone driven support for further development, testing, and analysis of existing intellectual property. A wide range of disciplines are represented in the project awards this cycle including biomedical engineering, chemistry, biochemistry, psychiatry, molecular genetics and microbiology, and pathology and dermatology.  Eight Feasibility awards and two Proof of Concepts awards have been funded this cycle. The recipients of this round of awards are: Feasibility Awards Therapeutic for Clostridium difficile antibiotic-associated diarrheal disease – Dr. James Bliska Device for rapid, simple and highly parallel single-cell processing – Dr. Eric Brouzes Developing a small molecule drug to treat systemic C. albicans infections – Dr. Nick Carpino Next generation hedgehog inhibitor for invasive basal cell carcinoma – Dr. Jiang Chen A Novel Strategy for Recombinant AAV Vector Production for Gene Therapy – Dr. Patrick Hearing A tandem-integration-based multi-barcode method for high-throughput combinatorial screening – Dr. Sasha Levy Novel CAIX Targeted Combination Inhibitor/PET tracer to treat patients with solid tumors – Dr. Peter Smith-Jones Substrate-Assisted Tethered Inhibitors of LigA to Treat MDR Gonorrhea – Dr. Peter Tonge Proof of Concept Awards fMRI Dynamic Phantom for Improved Detection of Resting-State Brain Networks - Dr. Lilianne Mujica-Parodi Development of SMASH technology as a next-gen sequencing diagnostic for congenital heart disease - Dr. Michael Ronemus ​“The announcement of this second cycle of awards from the Long Island Bioscience Hub under the NIH-REACH program is exemplary of the increasing commercially relevant research taking place in the region” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Coupled with the recent expansion of the Hub to include the Feinstein Institute and the announcement of our third “request for proposals,” the LIBH is steadily working toward its goal of accelerating the translation of these technologies from the bench to the bed side.” The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission. Download a PDF of the press release here.     [post_title] => Long Island Bioscience Hub Announces Next Funded Projects [post_excerpt] => The Center for Biotechnology, on Behalf of the Long Island Bioscience Hub (LIBH), has announced the recipients of the second round of funded projects under the Hub’s technology development and commercialization initiative. Funding for ten projects totaling $600,000 was awarded to applicants from the Hub’s partner institutions. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-bioscience-hub-announces-next-funded-projects [to_ping] => [pinged] => [post_modified] => 2016-05-05 13:47:58 [post_modified_gmt] => 2016-05-05 13:47:58 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2190 [menu_order] => 182 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3652 [post_author] => 3 [post_date] => 2021-02-03 16:41:22 [post_date_gmt] => 2021-02-03 16:41:22 [post_content] =>

BARDA is interested in learning more about the current landscape and technologies and companies in the needle-less delivery space. The delivery platforms should be compatible with biologic payloads (e. g. vaccines, monoclonal antibodies) that utilize the following alternative routes of administration:
- Oral
- Buccal/Sublingual
- Inhalation (e. g. aerosolization)
Other platforms

Technologies NOT of interest:
- Needle-based (e.g. auto injectors)
- Microneedle systems (e. g. patches)
- Implant-based

Particular interest in plug-and-play platforms that have potential to easily allow for the use of a wide variety of vaccines or therapeutics with the platform.

If you are interested in sharing information, please contact Phuong Nguyen at phuong.t.nguyen@stonybrook.edu

[post_title] => BARDA RFI: Needle-less Delivery [post_excerpt] => BARDA is interested in learning more about the current landscape and technologies and companies in the needle-less delivery space. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => barda-rfi-needle-less-delivery [to_ping] => [pinged] => [post_modified] => 2021-03-22 15:01:24 [post_modified_gmt] => 2021-03-22 15:01:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3652 [menu_order] => 54 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2510 [post_author] => 4 [post_date] => 2016-11-30 19:37:58 [post_date_gmt] => 2016-11-30 19:37:58 [post_content] => Codagenix, Inc. has entered into an exclusive licensing agreement with Stony Brook University, through the Research Foundation for the State of New York, to commercialize a platform technology to develop a pipeline of live attenuated vaccines against viral infections in people and animals. The technology relies on software to re-design the genomes of potentially harmful viruses to make them safe and effective vaccines. The technology stems from research in the laboratory of Eckard Wimmer, PhD, Distinguished Professor in the Department of Molecular Genetics & Microbiology. The lead indication for vaccine development generated is a vaccine against Seasonal Influenza slated for Phase I human clinical trials in 2017. Dr. Wimmer, along with Steffen Mueller, PhD, Codagenix President and Chief Science Officer, and J. Robert Coleman, PhD, Codagenix Chief Operating officer, worked as colleagues for years in Dr. Wimmer’s laboratory examining and experimenting with the genes of viruses. By collaborating with Stony Brook scientists Bruce Futcher, PhD, in the Department of Molecular Genetics & Microbiology, and Steven Skienna, PhD, in the Department of Computer Science, they discovered a way using gene manipulation and computer algorithms to “re-code” the genes of viruses. This re-coding process makes viruses extremely weak and thus ideal candidates as ultra-low dose attenuated vaccines. The licensing agreement enables Codgenix to develop and potentially market next generation vaccines using software-based gene design and whole viral synthesis to create low-dose, attenuated virus vaccines. The company expects to use this design to first test its vaccine against influenza; however, there are plans for human testing of their Zika and other vaccine candidates. Codagenix is also in partnership with a large agricultural company to make vaccines using the technology for companion and agricultural animals. The technology has been shown to be effective against numerous viruses including ZIka, Dengue, and RSV all of which are in preclinical testing. The development of this pipeline of vaccines can be seen in numerous scientific papers since 2008, including a paper in Science, PNAS, National Biotechnology and most recently in 2015 in MBIo. Read Stony Brook University's full press release here.  [post_title] => Codagenix Inks Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => codagenix-inks-exclusive-license-agreement [to_ping] => [pinged] => [post_modified] => 2017-03-15 13:49:05 [post_modified_gmt] => 2017-03-15 13:49:05 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2510 [menu_order] => 157 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4285 [post_author] => 4 [post_date] => 2023-09-11 12:13:16 [post_date_gmt] => 2023-09-11 16:13:16 [post_content] =>

Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”

The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.

Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include:
– Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital
– Doreen Swift, Senior Director, Embedded Software Engineering, IPS
– Michael R. Bielski, President, DevTech Partners
– Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University
– Paul Schwartz, Director, Advanced Propulsion Technologies

This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.

For more information visit: https://www.stonybrook.edu/commcms/ipp/Events/Manufacturing.php

[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23 [post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.” [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23 [to_ping] => [pinged] => [post_modified] => 2023-11-15 11:24:35 [post_modified_gmt] => 2023-11-15 16:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4285 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 251 [max_num_pages] => 84 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

“Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing” 10/12/23

More Information

Long Island Bioscience Hub Announces Next Funded Projects

More Information

BARDA RFI: Needle-less Delivery

More Information

Codagenix Inks Exclusive License Agreement

More Information